CD21 primes extrafollicular differentiation of autoreactive B cells in a TLR7-driven lupus model
Science Immunology · 2025
DOI: 10.1126/sciimmunol.ads8226 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Immunology, 2025. Verfasst von Danni Y Zhu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Program in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, USA. Hauptthemen laut MEDLINE: Toll-Like Receptor 7, Lupus Erythematosus, Systemic, Receptors, Complement 3d, B-Lymphocytes. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIAMS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
The extrafollicular (EF) B cell differentiation pathway has emerged as a prominent source of autoantibody-secreting cells (ASCs) in systemic lupus erythematosus (SLE). CD21 lo CD11c + B cells are associated with aging, infection, and autoimmunity. They are key contributors to EF ASCs, yet their developmental trajectory and receptor programming are unclear. To study EF mechanics of autoreactive B cells, we adoptively transferred naïve B cell populations into 564Igi mice, which act as an autoreactive host enriched for autoantigens and T cell help. Time-resolved analyses revealed a Toll-like receptor 7 (TLR7)–dependent early escape of peripheral tolerance and a pre–ASC division program. We identified naïve-derived CD21 lo cells as precursors of EF ASCs exhibiting elevated reliance on TLR7. Repertoire analysis delineated protoautoreactive B cell selection and receptor evolution toward self-reactivity. Continuous complement receptor 2 (CR2/CD21)–complement C3d and CD21–complement iC3b engagement triggered receptor down-regulation before proliferation. We reveal CD21 as an initiator of TLR7-dependent autoimmune EF proliferation and target for suppressing autoreactivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Program in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, USA.
- Harvard Graduate Program in Virology, Boston, USA.
- Department of Microbiology, Harvard Medical School, Boston, USA.
- Ragon Institute of Mass General, MIT, and Harvard, Cambridge, USA.
- Department of Medicine, Emory University School of Medicine, Atlanta, USA.
- Pfizer Centers for Therapeutic Innovation, Boston, USA.
ORCID-Profile: Danni Y Zhu, Daniel P Maurer, Carlos Castrillon, Minghe Ma, Jessica Min-Debartolo, Nathan Higginson-Scott, Aaron G Schmidt, Daniel Lingwood, Michael C Carroll
Förderung
- NIAID NIH HHS
- NIAMS NIH HHS
- National Institutes of Health
- Lupus Research Alliance
- Canadian Institutes of Health Research
Zitieren
APA
Zhu, D. Y., Maurer, D. P., Castrillon, C., Deng, Y., Mohamed, F. A. N., Ma, M., Tang, D., Min-Debartolo, J., Higginson-Scott, N., Buhlmann, J., Schmidt, A. G., Lingwood, D., & Carroll, M. C. (2025). CD21 primes extrafollicular differentiation of autoreactive B cells in a TLR7-driven lupus model. Science Immunology. https://doi.org/10.1126/sciimmunol.ads8226
Vancouver
Zhu DY, Maurer DP, Castrillon C, Deng Y, Mohamed FAN, Ma M, et al. CD21 primes extrafollicular differentiation of autoreactive B cells in a TLR7-driven lupus model. Science Immunology. 2025. doi:10.1126/sciimmunol.ads8226
BibTeX
@article{Zhu2025,
author = {Zhu, Danni Y and Maurer, Daniel P and Castrillon, Carlos and Deng, Yixiang and Mohamed, Faez A N and Ma, Minghe and Tang, David and Min-Debartolo, Jessica and Higginson-Scott, Nathan and Buhlmann, Janet and Schmidt, Aaron G and Lingwood, Daniel and Carroll, Michael C},
title = {CD21 primes extrafollicular differentiation of autoreactive B cells in a TLR7-driven lupus model},
journal = {Science Immunology},
year = {2025},
doi = {10.1126/sciimmunol.ads8226}
}
EUVIMED